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Abstract 
The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy 
and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promo‑
tion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to 
all stakeholders including the EAACI junior members. There was substantial progress in 2017 in the identification 
of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better 
understanding of molecular and cellular mechanisms, efforts for the development of biomarkers for disease predic‑
tion, novel prevention and intervention studies, elucidation of mechanisms of multimorbidies, entrance of new drugs 
in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen 
immunotherapy studies and metaanalyses have been the highlights of the last year.
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Introduction
The European Academy of Allergy and Clinical Immunol-
ogy (EAACI) has three official journals: Allergy, Pediatric 
Allergy and Immunology and Clinical and Translational 
Allergy. One of the major goals of EAACI is to support 
health promotion in which prevention and control of 
allergy plays a critical role and to disseminate the knowl-
edge of allergy to all stakeholders including the EAACI 
junior members.
The EAACI journals have reported on the prediction 
and primary and secondary prevention of allergic dis-
eases and asthma, and food allergy in 2016 [1, 2]. This 
paper summarises the achievements of 2017 in asthma 
and rhinitis. Completed and published EAACI task forces 
are listed in Table 1.
Prediction and prevention
The preventive role of nutrition in allergy and asthma is 
still a matter of debate and studies are ongoing. In the 
PACMA study (NL), breastfeeding was associated with a 
decreased risk of childhood asthma exacerbations later in 
life [3]. A meta-analysis found that fish intake in infancy 
could reduce the risk of eczema and allergic rhinitis in 
children, whereas maternal fish intake during pregnancy 
does not affect any atopic outcome. The intake of fish per 
se in infancy, not specially n-3 LC-PUFAs, may have an 
allergy protective effect. High-quality and adequately 
powered RCTs are however needed for a final conclusion 
[4]. However, a balance between primary prevention of 
allergic disease and optimal infant growth and nutrition 
should always be considered [5].
Is there a march from early food sensitization to later 
childhood allergic airway disease? Two prospective birth 
cohort studies [the high-risk Melbourne Atopic Cohort 
Study (MACS) (n = 620) and the population-based 
LISAplus (n = 3094)] showed that food sensitization (with 
or without aeroallergen sensitization) in the first 2 years 
of life increased the risk of subsequent asthma and aller-
gic rhinitis [6]. Life-course of atopy and allergy-related 
disease events are rarely studied in tropical sub-Saharan 
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Africa. 2345 Ugandan children were followed from birth 
to 9  years. Allergen sensitization started early in child-
hood and increased with age. Eczema and wheeze were 
common in infancy and declined with age. Atopy was 
strongly associated with asthma, rhinitis and eczema 
among the few affected children. Nevertheless, the typi-
cal Atopic March did not occur [7].
The early prediction of allergic diseases is one of the 
most important question in pediatric allergy. The pre-
dictive value of serum sST2 in preschool wheezers was 
observed for development of asthma with high FeNO 
[8]. A prospective birth cohort study (Danish Allergy 
Research Center cohort) identified early childhood risk 
factors for allergic and non-allergic rhinoconjunctivitis 
in adolescence [9]. Eczema which commences in early 
infancy and persists into toddler years is strongly asso-
ciated with asthma, and to a lesser extent hay fever, in 
high-risk children. If these associations are causal, pre-
vention of early-life eczema might reduce the risk of res-
piratory allergy [10]. Indoor fungal diversity in primary 
schools may differently influence allergic sensitization 
and asthma in children [11].
Long-term perinatal probiotic intervention was safe 
but efficacy was difficult to be confirmed in four rand-
omized, double-blind, placebo-controlled trials [12]. In 
Uganda, treating helminths during pregnancy and early 
childhood in the absence of change in other exposures, 
is unlikely to increase the risk of atopic diseases later in 
childhood [13].
Epidemiology
Birth decade affects the sensitization pattern and asthma 
risk were studied in Finnish adult population popula-
tion-based case–control data (N = 456). Sensitization to 
more than one allergen type and the number of positive 
SPT reactions associated with younger age and asthma. 
Atopic subjects aged 65 and above were characterized by 
sensitization to only one to two allergens [14].
The state of asthma epidemiology was assessed by the 
Task Force “Overview of Systematic Reviews in Allergy 
Epidemiology” of the EAACI Interest Group on Epide-
miology that proposed an overview of systematic reviews 
and their quality [15]. The same Task Force published an 
overview of systematic reviews in allergy epidemiology 
[16].
Multimorbidity
In allergic diseases, the term co-morbidity should be 
replaced by multimorbidity since the primary organ is 
unknown as indicated by a EAACI Task Force Report 
[17]. Several papers dealt with multimorbidity in the 
three journals. Allergen sensitization affects the change 
trend of prevalence of symptoms of rhinitis coexisting 
with wheeze among adolescents in Guangzhou City from 
1994 to 2009 [18]. Staphylococcus aureus enterotoxin 
sensitization is associated with allergic poly-sensitization 
and allergic multimorbidity in adolescents [19]. The gen-
der-shift in prevalence of allergic rhinitis and comorbid 
asthma from childhood to adulthood is more important 
in multimorbid disease [20].
There was no consistent evidence for an association of 
asthma or chronic rhinosinusitis with fruit and vegetable 
intake in this representative sample of European adults 
(Global Allergy and Asthma Network of Excellence 
 (GA2LEN) Survey) [21].
In rhinitis and asthma, CHRODIS criteria were applied 
to the MASK (Mobile Airways Sentinel NetworK) that 
has been recognized as a Good Practice [22].
Table 1 List of task force articles published
Manuscript title References
Overview of systematic reviews in allergy epidemiology [15]
Allergy in severe asthma [80]
The burden of nonadherence among adults with asthma: a role for shared decision‑making [48]
Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen‑induced rhinoconjunctivitis—an EAACI position 
paper
[81]
AllergoOncology—the impact of allergy in oncology: EAACI position paper [82]
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future—an EAACI Position Paper [26]
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Posi‑
tion Paper
[83]
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis—A EUFOREA‑ARIA‑EPOS‑
AIRWAYS ICP statement
[46]
Diagnostic tools in ocular allergy [84]
Work productivity in rhinitis using cell phones: the MASK pilot study [75]
Non‑allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology [85]
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Diagnosis
The diagnosis of allergy is changing with new in  vitro 
tests and the refinement of older ones. Diagnosing aller-
gic sensitizations in the third millennium is important 
and clinicians should know allergen molecule structures 
[23].
The high prevalence of food and respiratory sensiti-
zation supports the clinical guideline recommendation 
that allergies should be evaluated in all children with 
suspected asthma. The microarray platforms used found 
acceptable accuracy and provided refined IgE charac-
terization in 47% of the patients compared to standard 
extract-based methods [24]. The Pasture Study Group 
compared skin prick tests and specific IgE in 10-year-old 
children. Skin prick test and specific IgE display moder-
ate agreement, but have a similar Area Under the Curve 
for allergic diseases. At the cutoff value of 3 mm for skin 
prick test and 0.35 IU/mL for specific IgE, skin prick test 
T has a higher specificity for asthma and hay fever than 
specific IgE without difference for sensitivity [25].
Many allergen exposure chambers exist and a EAACI 
Position paper attempted to harmonize current concepts 
and projecting the needs for the future [26]. Peak nasal 
inspiratory flow was found to be as outcome for provoca-
tion studies in allergen exposure chambers in a  GA2LEN 
study [27].
Airways basophils may be of relevant important in the 
diagnosis of asthma [28]. They are increased and acti-
vated in eosinophilic asthma [29]. Sputum basophils are 
increased in eosinophilic asthma compared with non-
eosinophilic asthma phenotypes [30].
Some new markers may be useful in severe asthma 
including airway and peripheral urokinase plasminogen 
activator receptor [31] and CD48 on blood leukocytes 
[32]. Data from the large population-based cohort Swed-
ish  GA2LEN show that serum periostin relates to type-2 
inflammation and lung function in asthma [33]. As 
MicroRNAs (miRNAs), that regulate gene expression at 
the post-transcriptional level, are altered in asthma, cir-
culating miRNAs are attractive candidates for the iden-
tification of novel biomarkers.  Distinct plasma miRNAs 
are differentially regulated in human allergic asthma and 
were associated with clinical characteristics of patients. 
miRNA levels in plasma might have future potential to 
subphenotype patients with asthma [34].
Mechanisms
Studies on mechanisms and physiopathology of allergic 
diseases are becoming more and more important because 
of rapid developments on the concept of disease endo-
types and precision medicine. Local allergic rhinitis has 
been widely considered in the past decade but there is 
an evolution of concepts [35]. Allergic sensitization at 
school age is a systemic low-grade inflammatory disorder 
[36].
Farm exposure protects against development of aller-
gies early in life. High microbial diversity in the envi-
ronment has been associated with lower asthma risk, 
particularly in children exposed to farming.  A stronger 
inverse association of asthma with bacterial diversity 
in mattress dust as compared to nasal samples suggests 
microbial involvement beyond mere colonization of 
the upper airways [37]. At 4.5  years, protection against 
asthma by farm-milk exposure was partially mediated by 
regulatory T cells (Tregs). However, Tregs at the age of 
6 years were decreased with farm exposure and increased 
within asthmatics, opposite to age 4.5 years. This immu-
nological switch defines a critical ‘time window’ for Treg-
mediated asthma protection via environmental exposure 
before age 6 years [38].
PTTG1IP and MAML3 (pituitary tumour-transform-
ing 1 interacting protein (PTTG1IP) and rs345983 in 
Mastermind-like 3 (MAML3) are novel genomewide 
association genes for severity of hyperresponsiveness in 
adult asthma. The relevance of these genes is supported 
by co-expression of PTTG1lP with vimentin and E-cad-
herin-1 [39].
Epithelial barrier dysfunction is a central feature in the 
pathogenesis of allergic disease. Epithelial-to-mesenchy-
mal transition (EMT) has been proposed as one mecha-
nism afflicting barrier in asthma. A striking suppression 
of epithelial differentiation was found in asthma, over-
represented by insufficiency in insulin and Notch signal-
ing, but with the absence of conventional EMT markers 
[40]. EFNB2, FGFR1, FGFR2, INSR, IRS2, NOTCH2, 
TLE1, and NTRK2 were identified as novel markers cen-
tral to dysregulation of epithelial-mesenchymal signaling.
Other studies found that an altered fatty acid metabo-
lism and reduced stearoyl-coenzyme a desaturase activity 
in asthma [41]. Protein phosphatase 5 mediates corticos-
teroid insensitivity in airway smooth muscle in patients 
with severe asthma [42].
Treatment
Efficacy and safety of tiotropium was confirmed in 
school-age children with moderate-to-severe sympto-
matic asthma by a systematic review [43].
Although the main symptomatic treatment for rhi-
noconjunctivitis is intranasal corticosteroids (INCS) 
(daily or on demand) and oral antihistamines, it remains 
unclear which treatment provides the best relief of symp-
toms. A single-blinded randomized controlled trial 
in children (aged 6–18  years) with pollen-related AR. 
Patients received either INCS daily (fluticasone propion-
ate), INCS on demand (fluticasone propionate) or oral 
antihistamine on demand (levocetirizine) for 3  months 
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during the grass pollen season. This trial showed shows 
that INCS daily was not superior to INCS on demand 
or to antihistamine on demand regarding the number of 
symptom-free days. An on-demand INCS strategy has 
the advantage of a lower overall corticosteroid exposure 
and less costs [44].
Endotype-driven treatment in chronic upper airway 
diseases has been delineated in algorithms for allergic 
rhinitis and chronic rhinosinusitis [45]. This was the basis 
for the positioning the principles of precision medicine 
in care pathways for allergic rhinitis and chronic rhi-
nosinusitis—A EUFOREA-ARIA-EPOS-AIRWAYS ICP 
statement [46].
Lack of adherence in the treatment of asthma or rhi-
nitis is a major problem. Differences in medication 
adherence are associated with beliefs about medicines 
in asthma and COPD [47]. There is a role for shared 
decision-making to reduce the burden of nonadherence 
among adults with asthma [48]. Serious games in asthma 
education may help to improve adherence [49]. Mobile 
Health Intervention can be used in low-income, urban 
caregivers of children with asthma and may improve 
adherence [50].
Three papers on omalizumab provided new informa-
tion. Omalizumab effectively protects against early and 
late allergic responses in asthma after 4 weeks [51]. Lung 
function parameters may identify omalizumab responder 
patients [52]. Galectin-3 is an early predictive biomarker 
of modulation of airway remodeling in patients with 
severe asthma treated with omalizumab for 36  months 
[53].
Alternative treatments were also approached. Lung 
function improvement and airways inflammation reduc-
tion were observed in asthmatic children after a reha-
bilitation program at moderate altitude [54]. Some 
guidelines were proposed to treat food allergy with an 
impact on airway diseases [55, 56].
Immunotherapy
A large number of studies and meta-analyses were pub-
lished in 2017. Systematic reviews of allergen immu-
notherapy were published for allergic asthma and 
rhinoconjunctivitis [57–60], the prevention of allergy 
[61], and IgE-mediated food allergy [62]. They were 
used to provide evidence for the large consensus on 
immunotherapy carried out by EAACI. The first EAACI 
guidelines on allergen immunotherapy concerned the 
prevention of allergy [63]. Efficacy of allergen immuno-
therapy in reducing the likelihood of developing new 
allergen sensitizations was questioned in a systematic 
review [64]. Pooled efficacy and safety data for house 
dust mite sublingual immunotherapy tablets were stud-
ied in adolescents [65].
Clinical benefits and safety were published for the 
treatment of patients with SQ house dust mite sub-
lingual tablet in house dust mite allergic rhinitis [66], 
house dust mite sublingual tablet rhinitis [67], sublingual 
monomeric allergoid tablets in house dust mite-allergic 
patients [68] and rBet v 1-FV in birch-related soya allergy 
[69].
The role of immunotherapy in elderly patients should 
be confirmed. A randomized, double-blind placebo-con-
trolled trial found it was effective [70].
European Survey on Adverse Systemic Reactions in 
Allergen Immunotherapy (EASSI) represent a real-life 
clinical assessment in adults [71] and children [72]. 4316 
adults were studied. A total of 109 SRs were recorded. 
Immunotherapy for respiratory allergy is safe, with a 
low number of SRs observed in real-life clinical practice. 
A personalized analysis of risk factors could be used to 
minimize systemic reactions.  1563 children (mean ± SD 
age: 11.7 ± 3.9 years; rhinitis: 93.7%; asthma: 61.5%; poly-
sensitization: 62.5%) were assessed. 24 patients experi-
enced severe systemic reactions. In a real-life pediatric 
setting, systemic reactions are infrequent and generally 
not severe. Pollen polysensitization, grass pollen extracts 
and natural extracts (vs. allergoids) were risk factors for 
AIT-associated systemic reactions.
Costs
The comparison of costs of different treatment 
approaches has been an unmet need and requires exten-
sive studies. The Canadian Respiratory Research Network 
studied the 10-year trends in direct costs of asthma. This 
population-based study on 341,457 individuals (mean 
age at entry 27.3, 54.1% female) showed that excess costs 
in patients with asthma were $1028.0 (95% CI $982.7–
$1073.4) per patient-year (PY). Medications contributed 
to the greatest share of excess costs ($471.7/PY). There 
was a 2.9%/year increase in excess costs, a combination 
of asthma-attributable costs declining by 0.8%/year while 
excess costs unrelated to asthma increasing by 3.8%/year. 
The most dramatic trend was observed in asthma-related 
outpatient costs, which decreased by %6.6/year [73].
Estimate of the total costs of allergic rhinitis in special-
ized care in Spain was based on real-world data (FERIN 
Study) [74]. The total mean cost of AR per patient-year 
(n = 498) was € 2326.70 (direct, 553.80; indirect, 1772.90). 
The total cost of AR for society is considerable. A reduc-
tion in presenteeism would generate considerable savings 
for society. Work productivity is largely impaired in days 
with uncontrolled rhinitis [75]. Costs of perennial aller-
gic rhinitis and allergic asthma increase with severity and 
poor disease control [76].
In a Portuguese nationwide, population-based, cost-
of-illness study, costs of childhood asthma are high 
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(0.9% of the healthcare expenditures in Portugal). 
Direct costs represented three-fourth of total costs, 
mainly related to the use of healthcare services for 
acute asthma care [77].
Political agenda
Allergic diseases and asthma represent over 25% of 
the European population and cause a very high bur-
den. Strategies for early diagnosis, prevention and con-
trol need to be anchored on a strong political agenda 
to implement the results of the research into practice. 
Two important political activities at the EU Parliament 
were reported in the journals: A European Summit on 
the Prevention and Self-Management of Chronic Res-
piratory Diseases (29 March 2017) [78] and a European 
symposium on the awareness of allergy for the promo-
tional campaign (26–28 April 2016) [79].
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